
Wearable Microfluidic Systems for Measuring Sweat Biomarkers in Cystic Fibrosis Patients During Exercise in Remote SettingsAward last edited on: 4/18/2023
Sponsored Program
SBIRAwarding Agency
NIH : NHLBITotal Award Amount
$299,936Award Phase
1Solicitation Topic Code
838Principal Investigator
Stephen P LeeCompany Information
Epicore Biosystems Inc
810 Memorial Drive Suite 100
Cambridge, MA 02139
Cambridge, MA 02139
(857) 529-7776 |
info@epicorebiosystems.com |
www.epicorebiosystems.com |
Location: Single
Congr. District: 07
County: Middlesex
Congr. District: 07
County: Middlesex
Phase I
Contract Number: 1R43HL162246-01Start Date: 8/5/2022 Completed: 8/31/2023
Phase I year
2022Phase I Amount
$299,936Public Health Relevance Statement:
Project narrative:
Cystic fibrosis (CF) is caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene which lead to impaired chloride (Cl-) movement across the plasma membrane. Individuals with CF typically excrete sweat with substantially higher Cl- and sodium (Na+) concentrations than healthy individuals. There is substantial data that has described sweat rates and electrolyte loss in response to exercise in normal athletes, however, there is limited data for CF patients. The present proposal addresses this unmet need by deploying novel wearable sweat sensors that provide quantitative and actionable hydration and electrolyte repletion measurements for adult CF patients taking CF therapies. The foundational insights from this work will enable new care management paradigms for CF patients in remote settings.
Project Terms:
Phase II
Contract Number: ----------Start Date: 00/00/00 Completed: 00/00/00